This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

Biotech stocks were largely flat Monday, as research-and-development successes and ratings upgrades edged some players higher.

Biopharmaceutical company Viragen's (VRA - Get Report) shares climbed 2 cents, or 24%, to 9 cents on Monday after reporting that researchers were able to improve a process for creating a human protein used to treat hepatitis C and certain malignant diseases.

Another biopharmaceutical company, MGI Pharma (MOGN), and its Swiss partner Helsinn Healthcare announced they had submitted a supplemental new drug application for anti-post-operative nausea treatment Aloxi Injection to the Food and Drug Administration. Aloxi is already approved by the FDA for the prevention of nausea and vomiting in certain cases of emetogenic cancer chemotherapy. Shares rose 38 cents, or 1.7%, to $22.44.

Additionally, BioSante Pharmaceuticals (BPA) signed an exclusive agreement with Pantarhei Bioscience, a Netherlands-based pharmaceutical company, to develop and market a new birth control pill in the U.S. It will co-fund the early development of the oral contraceptive up to $1 million and will receive royalty payments on U.S. sales. Shares leapt 38 cents, or 5.6%, to $7.13.

Ratings drove other stocks higher. Albany Molecular Research (AMRI - Get Report) climbed 2.7% after Jeffries & Co. changed their rating for the chemistry services and drug-discovery company to buy from hold. Similarly, Deutsche Bank upgraded hospice-care services company Chemed to buy from hold, sending shares up 28 cents to $11.30.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CGPI $0.00 0.00%
AMRI $15.06 -2.50%
BSX $16.06 -3.40%
JNJ $102.00 1.50%
VRA $14.62 2.60%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,854.30 -25.75 -1.37%
NASDAQ 4,285.8540 -77.29 -1.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs